Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development of an insulin and glucagon combination product that the company has been in the process of developing for approximately 18 months. “We’re very excited that this round is able to get us positioned for a successful series A once we meet some internal confidential milestones,” Edward Raskin, CEO of Abvance, told BioWorld. Read More
Many cancers involve upregulation of Aurora kinase B, which helps deregulate normal cell cycling to drive tumor proliferation. The kinase should therefore be a good therapeutic target, yet no small-molecular inhibitor has been clinically approved despite more than two decades of effort. Read More
The U.S. FDA has cleared Rocket Pharmaceuticals Inc.’s IND application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated dilated cardiomyopathy (BAG3-DCM), a severe form of heart failure. Read More
Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 (Ac-225) to target a non-prostate-specific member antigen (PSMA) protein that is frequently overexpressed in several tumor types, including prostate cancer. Read More
Sunshine Lake Pharma Co. Ltd. has disclosed Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis. Read More
MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials. Read More
Monoclonal antibodies show strong therapeutic potential against neurodegenerative diseases, but a major challenge is ensuring that they can arrive unharmed in the brain at sufficient concentrations. One way around this challenge is to vectorize the monoclonal antibody: encode it within a vector that can infect target cells in the brain and express the antibody in situ. Read More
Shemyakin Institute of Bioorganic Chemistry has synthesized perylenylethynylphenol derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19). Read More
Institut National Supérieur des Sciences Agronomiques de l’Alimentation et de l'Environnement has identified compounds reported to be useful for the treatment of cryptosporidiosis.
Read More
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant cancers, with limited therapeutic options and poor survival rates. The development of targeted therapies that disrupt multiple signaling pathways simultaneously could offer new opportunities to improve outcomes in this disease.
The efficacy of camptothecin-based topoisomerase I (Topo1) inhibitors, which are widely used as anticancer therapies, is often limited by resistance mechanisms, primarily involving mutations in the Topo1 enzyme and increased drug efflux mediated by ATP-binding cassette (ABC) transporters, particularly ABCG2 (BCRP). Read More
Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane antigen (PSMA)-targeted radiotheranostic agent, [177Lu]PSMA-VG-01, for the treatment of metastatic castration-resistant prostate cancer. Read More
Pfizer Inc. has described nucleoprotein N (respiratory syncytial virus [RSV]) inhibitors reported to be useful for the treatment of RSV infection. Read More
